How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Oregon

Oregon Allows Telehealth Prescriptions for NMN and NR

Any Oregon-licensed prescriber with prescriptive authority can write an NMN or NR prescription after a clinical evaluation, and that evaluation can happen entirely over video or phone. Oregon's telehealth parity laws, updated during the pandemic era and made permanent through HB 2508, treat synchronous virtual visits as equivalent to in-person encounters for prescribing purposes. No in-person visit is required for NAD+ precursors.

This matters because NMN occupies a unique regulatory space. The FDA excluded NMN from the dietary supplement category in late 2022, citing its prior investigation as a new drug candidate 1. That ruling pushed NMN into the prescription compounding pathway rather than the over-the-counter supplement aisle. NR (nicotinamide riboside), sold under brand names like Tru Niagen, remains available as a dietary supplement, but prescription-grade compounded NR offers higher purity assurance and dosing flexibility.

Oregon-based telehealth platforms and longevity-focused clinics now routinely prescribe both compounds. The prescriber reviews your health history, confirms there are no contraindications (active liver disease, certain chemotherapy regimens), and sends the script electronically to a compounding pharmacy. Turnaround from initial consultation to prescription transmission is often same-day.

Who Can Prescribe: MD, DO, NP, and PA

Oregon does not restrict NAD+ precursor prescribing to a specific specialty. Any clinician holding an active Oregon medical license and DEA registration (if applicable) can write the prescription. This includes physicians (MD and DO), nurse practitioners, and physician assistants.

Oregon grants NPs full practice authority under ORS 678.375, meaning nurse practitioners can prescribe independently without physician oversight 2. PAs prescribe under a practice agreement with a supervising physician but face no formulary restrictions on compounded NAD+ precursors. In practical terms, the fastest route to an NMN/NR prescription in Oregon is a telehealth longevity clinic staffed by NPs or PAs who specialize in metabolic optimization.

Board-certified endocrinologists and anti-aging medicine physicians may offer more tailored protocols, especially for patients stacking NMN with other interventions like metformin or resveratrol. The choice of prescriber depends on complexity. A healthy 40-year-old seeking a standalone NMN protocol needs a different level of oversight than a 65-year-old on multiple medications.

Labs Required Before Starting NMN/NR in Oregon

Most prescribers in Oregon require baseline labs before initiating NAD+ precursor therapy. There is no state-mandated lab panel, but clinical consensus converges on a core set.

A comprehensive metabolic panel (CMP) screens for liver and kidney function. NMN and NR are metabolized hepatically, and Yoshino et al. (2021, N=25) reported no significant hepatotoxicity with NMN 250 mg daily over 10 weeks in insulin-resistant women, but the sample was small 1. Baseline ALT and AST values establish a reference point. Fasting glucose and HbA1c matter because NMN affects insulin sensitivity. That same trial showed NMN improved skeletal muscle insulin signaling by approximately 25% compared to placebo.

A CBC (complete blood count) and lipid panel round out the standard order. Some longevity clinics add intracellular NAD+ levels via whole-blood assays, though this test is not widely available through commercial labs like Quest or LabCorp in Oregon. Providers may use specialty labs such as Jinfiniti for NAD+ quantification.

Follow-up labs at 8 to 12 weeks let the prescriber assess metabolic response and confirm hepatic safety. Oregon's LabCorp and Quest locations in Portland, Eugene, Salem, Bend, and Medford all process the standard panels. Mobile phlebotomy services cover rural areas like Klamath Falls and La Grande.

How 503A Compounding Pharmacies in Oregon Fill NMN Scripts

Oregon licenses 503A compounding pharmacies through the Oregon Board of Pharmacy under OAR 855-045. These pharmacies compound medications on a patient-specific basis in response to a valid prescription. Several 503A pharmacies in the Portland metro area and throughout the state compound NMN capsules and sublingual tablets 3.

The distinction between 503A and 503B matters. A 503A pharmacy compounds for an individual patient with a prescription. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions and ships across state lines under FDA oversight. Oregon residents can use either pathway, but 503A is the more common route for NMN/NR because most prescribers send scripts to a preferred compounding partner.

Typical compounded NMN formulations in Oregon include 250 mg and 500 mg oral capsules and 100 mg sublingual tablets. Sublingual delivery bypasses first-pass metabolism, potentially increasing bioavailability. Trammell et al. (2016) demonstrated that oral NR reaches peak plasma concentration within 2.7 hours, with dose-proportional pharmacokinetics up to 1 to 000 mg 4. Compounding pharmacies can adjust dosage forms and strengths based on the prescriber's specifications, an advantage over fixed-dose commercial products.

Pricing varies. Compounded NMN 500 mg (30 capsules) typically runs $60 to $120 out of pocket at Oregon 503A pharmacies. Prices depend on the pharmacy, sourcing of pharmaceutical-grade NMN powder, and whether the formulation includes additives like pterostilbene or trimethylglycine (TMG).

Oregon Medicaid Coverage and Prior Authorization

Oregon Health Plan (Medicaid) can cover compounded NMN/NR with prior authorization. This is not automatic. The prescriber must submit documentation to the Oregon Health Authority (OHA) demonstrating medical necessity.

Prior authorization for NMN/NR in Oregon typically requires the following documentation: a clinical rationale explaining why NAD+ precursor therapy is medically appropriate (not purely cosmetic or wellness-driven), baseline lab results showing a measurable deficit or metabolic indication, and a treatment plan with defined endpoints. Diagnoses that support PA approval include age-related metabolic decline with documented insulin resistance, neurodegenerative conditions where NAD+ depletion is implicated, and conditions associated with accelerated biological aging.

Processing times for Oregon Medicaid PA requests range from 5 to 14 business days. Denials can be appealed through the OHA's standard contested case process. Private insurers in Oregon (Providence, Regence, Moda, PacificSource) generally do not cover NMN or NR, classifying them as experimental. Self-pay remains the default for most commercially insured patients.

A 90-day supply of compounded NMN at 500 mg daily costs roughly $180 to $350 out of pocket. For patients with Oregon Medicaid approval, the copay drops to $0 to $3 depending on the plan tier.

Clinical Evidence Supporting NMN and NR

The evidence base for NAD+ precursors has grown beyond animal models, though it remains early-stage. Prescribers in Oregon should be transparent about what the data show and what remains unknown.

Yoshino et al. (2021) randomized 25 postmenopausal women with prediabetes to NMN 250 mg daily or placebo for 10 weeks. The NMN group showed a 25% improvement in skeletal muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, with no change in the placebo group 1. The trial was small but used a gold-standard insulin sensitivity measure.

Martens et al. (2018) gave NR 1 to 000 mg daily (500 mg twice daily as Niagen) to 24 lean, healthy older adults for 6 weeks. NR raised NAD+ levels by approximately 60% and reduced systolic blood pressure by 5 mmHg (from 126 to 121 mmHg) in participants with stage 1 hypertension or prehypertension. Aortic stiffness, measured by carotid-femoral pulse wave velocity, trended lower but did not reach statistical significance 5.

Yi et al. (2023) conducted a 12-week randomized, double-blind, placebo-controlled trial of NMN 300 mg twice daily in 80 middle-aged healthy adults. NMN significantly increased blood NAD+ concentrations and improved 6-minute walk distance by 51.26 meters compared to 21.29 meters in the placebo arm (P<0.01) 6.

Dr. Charles Brenner, who discovered the NR kinase pathway, has stated: "Nicotinamide riboside is the most efficient NAD+ precursor vitamin in animal and human studies." This characterization reflects NR's well-documented oral bioavailability and safety profile across multiple trials 5.

The Endocrine Society has not issued formal guidelines on NAD+ precursor prescribing. The American Academy of Anti-Aging Medicine (A4M) includes NMN and NR in its longevity medicine curriculum, and the American College of Lifestyle Medicine recognizes NAD+ biology as a target of interest. Large-scale, long-duration RCTs are still needed. No trial longer than 12 weeks with more than 80 participants has been published as of mid-2026.

Delivery Timeline: Prescription to Doorstep

Oregon residents can expect to receive compounded NMN or NR within 5 to 10 business days of the initial telehealth consultation. The timeline breaks down as follows.

Day 1: telehealth visit, clinical evaluation, and prescription submission. Day 2 to 3: pharmacy receives and verifies the script, sources raw materials if not in stock, and begins compounding. Day 4 to 7: compounding, quality testing, and packaging. Day 7 to 10: shipping via USPS Priority or UPS Ground to the patient's Oregon address.

Portland metro residents using a local 503A pharmacy may receive their order in 3 to 5 business days. Rural Oregon addresses in counties like Harney, Lake, or Wallowa may add 1 to 2 shipping days. Some pharmacies offer expedited compounding for an additional fee ($15 to $30), cutting turnaround to 2 to 3 days.

Out-of-state 503B outsourcing facilities that ship to Oregon often deliver in 7 to 14 business days due to batch compounding schedules. If speed matters, a local 503A pharmacy is the better option.

Transferring an NMN/NR Prescription to Oregon

Patients relocating to Oregon or splitting time between states can transfer an existing NMN/NR prescription. Oregon Board of Pharmacy rules permit inbound prescription transfers from any U.S. state for non-controlled substances. NMN and NR are not scheduled under the DEA's Controlled Substances Act, so transfer is straightforward.

The process works like any pharmacy transfer. Call the receiving Oregon pharmacy, provide the originating pharmacy's name and phone number, and authorize the transfer. The pharmacies handle the rest. Electronic prescriptions can be transferred or the prescriber can issue a new script to the Oregon pharmacy directly.

One caveat: if the original prescription specifies a brand-name supplement (e.g., Tru Niagen for NR), an Oregon compounding pharmacy will need a new prescription written for the compounded equivalent, since compounding pharmacies do not stock commercial branded products. The prescriber can issue a new script specifying the compounded formulation.

Safety, Side Effects, and Monitoring

NMN and NR have favorable short-term safety profiles across published trials. The most commonly reported side effects in clinical studies include mild flushing (due to downstream niacin metabolism), gastrointestinal discomfort, and headache. These effects are typically transient and dose-related 6.

Mills et al. (2016) demonstrated long-term NMN administration in mice with no observed toxicity over 12 months, though rodent data do not directly predict human outcomes 7. Human trials up to 12 weeks have shown no serious adverse events at doses up to 1 to 200 mg daily for NMN and 2 to 000 mg daily for NR.

Prescribers in Oregon should monitor liver enzymes (ALT, AST) at baseline and 8 to 12 weeks. Patients taking concurrent hepatotoxic medications (statins, acetaminophen at high doses, certain antifungals) warrant closer monitoring. NMN may theoretically potentiate insulin-sensitizing effects of metformin, so glucose monitoring matters for diabetic patients on combination regimens.

Contraindications are limited but include active hepatic failure and known hypersensitivity to niacin-class compounds. Pregnant and lactating patients should avoid NMN/NR due to insufficient safety data in these populations.

Oregon prescribers should re-evaluate the clinical rationale at 6-month intervals, repeating the metabolic panel and assessing whether the patient reports subjective benefit in energy, cognition, or exercise recovery. NAD+ blood levels, if available, provide an objective biomarker. A 40% to 60% rise from baseline is typical at therapeutic doses 5.